This multicenter analysis evaluated genomic profiles, risk stratification approaches, and post-transformation treatment outcomes in patients with small-cell lung cancer (SCLC) transformed from a prior lung cancer histology (likely EGFR-mutant NSCLC), examining molecular drivers and therapeutic responses after transformation.
Full paper text was not provided; specific results, sample sizes, and outcome data cannot be verified or extracted.
Explore related topics
